Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer

被引:14
|
作者
Wada, Miku [1 ]
Kukita, Asako [1 ]
Sone, Kenbun [1 ]
Hamamoto, Ryuji [2 ,3 ]
Kaneko, Syuzo [2 ]
Komatsu, Masaaki [2 ,3 ]
Takahashi, Yu [1 ]
Inoue, Futaba [1 ]
Kojima, Machiko [1 ]
Honjoh, Harunori [1 ]
Taguchi, Ayumi [1 ]
Kashiyama, Tomoko [1 ]
Miyamoto, Yuichiro [1 ]
Tanikawa, Michihiro [1 ]
Tsuruga, Tetsushi [1 ]
Mori-Uchino, Mayuyo [1 ]
Wada-Hiraike, Osamu [1 ]
Osuga, Yutaka [1 ]
Fujii, Tomoyuki [1 ]
机构
[1] Univ Tokyo, Dept Obstet & Gynecol, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan
[2] Natl Canc Ctr, Div Mol Modificat & Canc Biol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[3] RIKEN Ctr Adv Intelligence Project, Canc Translat Res Team, Chuo Ku, 1-4-1 Nihonbashi, Tokyo 1030027, Japan
关键词
epigenetic modifier; histone methyltransferase; SETD8; high-grade serous ovarian cancer; UNC0379; HISTONE; METHYLATION; P53; ACTIVATION; EXPRESSION;
D O I
10.3390/biom10121686
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The histone methyltransferase SETD8, which methylates the lysine 20 of histone H4 (H4K20), is reportedly involved in human carcinogenesis along with nonhistone proteins such as p53. However, its expression profiles and functions in the context of high-grade serous ovarian carcinoma (HGSOC) are still unknown. The purpose of this study was to investigate the role of SETD8 in HGSOC. We performed quantitative real-time PCR and immunohistochemistry to detect the expression of SETD8 in HGSOC samples and normal ovarian specimens. Then, we assessed the effect of the inhibition of SETD8 expression using small interfering RNA (siRNA) and a selective inhibitor (UNC0379) on cell proliferation and apoptosis in HGSOC cells. The expression of SETD8 was significantly upregulated in clinical ovarian cancer specimens compared to that in the corresponding normal ovary. In addition, suppression of SETD8 expression in HGSOC cells with either siRNA or UNC0379 resulted in reduced levels of H4K20 monomethylation, inhibition of cell proliferation, and induction of apoptosis. Furthermore, UNC0379 showed a long-term antitumor effect against HGSOC cells, as demonstrated by colony-formation assays. SETD8 thus constitutes a promising therapeutic target for HGSOC, warranting further functional studies.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [31] PAX8-directed nanotherapeutics for high-grade serous ovarian cancer.
    Chandrasekaran, Akshaya
    Ahmed, Mariam
    Holub, Nicole
    Wang, Wade
    Hammond, Paula T.
    Elias, Kevin M.
    CANCER RESEARCH, 2021, 81 (13)
  • [32] FKBPL as a novel therapeutic target and prognostic biomarker in high grade serous ovarian cancer
    Annett, Stephanie
    Moore, Gillian
    Short, Amy
    Moustafa, Neermeen
    Das, Sudipto
    O'Connor, Darran
    McCrudden, Cian
    Kissenpfenning, Adrien
    Nelson, Laura
    Harley, Ian
    Arthur, Ken
    Yakkundi, Anita
    McCluggage, Glen
    Marshall, Andrea
    Furlong, Fiona
    McCarthy, Helen O.
    Cotton, Graham
    Harrison, Timothy
    McClements, Lana
    Robson, Tracy
    CANCER RESEARCH, 2018, 78 (13)
  • [33] Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma
    Kurimchak, Alison M.
    Herrera-Montavez, Carlos
    Brown, Jennifer
    Johnson, Katherine J.
    Sodi, Valerie
    Srivastava, Nishi
    Kumar, Vikas
    Deihimi, Safoora
    O'Brien, Shane
    Peri, Suraj
    Mantia-Smaldone, Gina M.
    Jain, Angela
    Winters, Ryan M.
    Cai, Kathy Q.
    Chernoff, Jonathan
    Connolly, Denise C.
    Duncan, James S.
    SCIENCE SIGNALING, 2020, 13 (619)
  • [34] Principles of dormancy evident in high-grade serous ovarian cancer
    Trevor G. Shepherd
    Frederick A. Dick
    Cell Division, 17
  • [35] The peritoneal tumour microenvironment of high-grade serous ovarian cancer
    Leinster, D. Andrew
    Kulbe, Hagen
    Everitt, Gemma
    Thompson, Richard
    Perretti, Mauro
    Gavins, Felicity N. E.
    Cooper, Dianne
    Gould, David
    Ennis, Darren P.
    Lockley, Michelle
    McNeish, Iain A.
    Nourshargh, Sussan
    Balkwill, Frances R.
    JOURNAL OF PATHOLOGY, 2012, 227 (02): : 136 - 145
  • [36] Centrosomes - The Achilles' heel of high-grade serous ovarian cancer?
    Chandrasekaran, G.
    Hall, D.
    Vias, M.
    Brenton, J. D.
    Gergely, F.
    MOLECULAR BIOLOGY OF THE CELL, 2015, 26
  • [37] Determinants of resistance and response in high-grade serous ovarian cancer
    Bowtell, David D. L.
    CLINICAL CANCER RESEARCH, 2016, 22
  • [38] Novel strategies for targeting high-grade serous ovarian cancer
    Perets, Ruth
    Wyant, Gregory A.
    Ohman, Anders W.
    Setlur, Sunita R.
    Crum, Christopher P.
    Drapkin, Ronny
    Dinulescu, Daniela M.
    CLINICAL CANCER RESEARCH, 2015, 21
  • [39] Evolution of platinum resistance in high-grade serous ovarian cancer
    Cooke, Susanna L.
    Brenton, James D.
    LANCET ONCOLOGY, 2011, 12 (12): : 1169 - 1174
  • [40] Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer
    Freimund, Alison E.
    Beach, Jessica A.
    Christie, Elizabeth L.
    Bowtell, David D. L.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2018, 32 (06) : 983 - +